Royalty Pharma Sub-Manager, LLC
Royalty Pharma Sub-Manager, LLC reported 4 US-listed holdings worth $241.9 million in its 13F for the quarter ended 30 June 2026, filed 21 August 2026. Its largest: Cytokinetics Inc. (34.5%), Zenas Biopharma Inc. (25.1%) and Kailera Therapeutics Inc. (22.4%). Against the quarter before, it opened 1 position, added to 0, trimmed 0 and sold out of 1.
The 4 largest of its 4 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +15.3% over the 2 quarters to 30 June 2026, against +9.5% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 1
- Kailera Therapeutics Inc. KLRA$54.1 million
Sold out of 1
- Biocryst Pharmaceuticals Inc. BCRX$36.6 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Cytokinetics Inc. CYTK | 980.4K | $83.5 million | 34.52% | no change |
| Zenas Biopharma Inc. ZBIO | 2.4M | $60.6 million | 25.05% | no change |
| Kailera Therapeutics Inc. KLRA | 2.5M | $54.1 million | 22.36% | new |
| Biohaven Ltd BHVN | 2.9M | $43.7 million | 18.06% | no change |